BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 8883930)

  • 1. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression.
    Hung HC; Lee EH
    Brain Res Mol Brain Res; 1996 Sep; 41(1-2):14-26. PubMed ID: 8883930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways.
    Hung HC; Lee EH
    Free Radic Biol Med; 1998 Jan; 24(1):76-84. PubMed ID: 9436616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-Methyl-4-phenyl-pyridinium (MPP+) uptake does not explain the differential toxicity of MPP+ in the nigrostriatal and mesolimbic dopaminergic pathways.
    Hung HC; Tao PL; Lee EH
    Neurosci Lett; 1995 Aug; 196(1-2):93-6. PubMed ID: 7501267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential interactive effects of gliotoxin and MPTP in the substantia nigra and the locus coeruleus in BALB/c mice.
    Chang FW; Wang SD; Lu KT; Lee EH
    Brain Res Bull; 1993; 31(3-4):253-66. PubMed ID: 7683960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
    Kozina EA; Khakimova GR; Khaindrava VG; Kucheryanu VG; Vorobyeva NE; Krasnov AN; Georgieva SG; Kerkerian-Le Goff L; Ugrumov MV
    J Neurol Sci; 2014 May; 340(1-2):198-207. PubMed ID: 24768159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recovery of nigrostriatal and mesolimbic dopaminergic system following administration of ganglioside in MPTP-treated mice].
    Date I; Asari S; Nishimoto A; Felten DL
    No To Shinkei; 1990 Nov; 42(11):1035-40. PubMed ID: 2076347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of L-deprenyl on MPP+- and MPTP-induced dopamine overflow in microdialysates of striatum and nucleus accumbens.
    Wu WR; Zhu ZT; Zhu XZ
    Life Sci; 2000 Jun; 67(3):241-50. PubMed ID: 10983868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice.
    Moy LY; Albers DS; Sonsalla PK
    Brain Res; 1998 Apr; 790(1-2):264-9. PubMed ID: 9593931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
    Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
    Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different susceptibility to 1-methyl-4-phenylpyridium (MPP(+))-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B).
    Ito T; Suzuki K; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):153-8. PubMed ID: 21855308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions.
    Fornai F; Alessandrì MG; Torracca MT; Bassi L; Corsini GU
    J Pharmacol Exp Ther; 1997 Oct; 283(1):100-7. PubMed ID: 9336313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of nigrostriatal dopaminergic transmission by antisense oligodeoxynucleotide against brain-derived neurotrophic factor.
    Lau YS; Hao R; Fung YK; Fu LS; Bishop JF; Pfeiffer RF; Mouradian MM
    Neurochem Res; 1998 Apr; 23(4):525-32. PubMed ID: 9566587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional and temporal expression of the peripheral benzodiazepine receptor in MPTP neurotoxicity.
    Kuhlmann AC; Guilarte TR
    Toxicol Sci; 1999 Mar; 48(1):107-16. PubMed ID: 10330690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative synthesis of dopamine by non-dopaminergic neurons as a compensatory mechanism in the striatum of mice with MPTP-induced Parkinsonism.
    Kozina EA; Kim AR; Kurina AY; Ugrumov MV
    Neurobiol Dis; 2017 Feb; 98():108-121. PubMed ID: 27940203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration : early loss of TH in striosomes after methamphetamine.
    Granado N; Ares-Santos S; O'Shea E; Vicario-Abejón C; Colado MI; Moratalla R
    Neurotox Res; 2010 Jul; 18(1):48-58. PubMed ID: 19760475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Jackson-Lewis V; Jakowec M; Burke RE; Przedborski S
    Neurodegeneration; 1995 Sep; 4(3):257-69. PubMed ID: 8581558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones.
    Wüllner U; Löschmann PA; Schulz JB; Schmid A; Dringen R; Eblen F; Turski L; Klockgether T
    Neuroreport; 1996 Mar; 7(4):921-3. PubMed ID: 8724674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways.
    Peltonen I; Myöhänen TT; Männistö PT
    Neurochem Res; 2012 Sep; 37(9):2033-41. PubMed ID: 22729983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis.
    Fuxe K; Janson AM; Rosén L; Finnman UB; Tanganelli S; Morari M; Goldstein M; Agnati LF
    Exp Brain Res; 1992; 88(1):117-30. PubMed ID: 1347270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.
    Han M; Huang XF; Deng C
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):941-52. PubMed ID: 19203411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.